In November 2025, Rana McKay, MD initiated a phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC). DelveInsight's Bone ...
PPGLs show marked skeletal tropism, with 75.7% of patients developing bone metastases, primarily in the spine, after surgical resection.
Capital Market on MSN
Zydus Lifesciences gains after launching denosumab biosimilar
Denosumab is a monoclonal antibody with several indications related to bone health, primarily used in the treatment of ...
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...
Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. The company has launched Zyrifa, a ...
Zydus introduces biosimilar denosumab 120 mg SC – protecting bone health in cancer patients: Our Bureau, Mumbai Wednesday, December 10, 2025, 13:30 Hrs [IST] Zydus Lifesciences ...
Zydus Life noted that population-scale studies show high rates of bone involvement, affecting 50-70% of advanced breast or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback